Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: Clinical and observational studies suggest that use of thiazolidinediones (TZDs) is associated with an increased fracture risk. In addition, type 2 diabetes mellitus (T2DM) is a risk factor for osteoporotic fracture. Our aim was to estimate fracture risks in TZD users and users of other antidiabetic drugs, classified according to proxies of disease severity. Methods: We conducted a population‐based cohort study utilizing the Dutch PHARMO database (1998–2008). PHARMO links pharmacy‐dispensing data to the National Hospital Registry. Oral antidiabetic users (n = 123 452) were matched 1:4 by year of birth and sex to non‐users. Cox proportional hazards models were used to estimate hazard ratios (HRs) of fracture in TZD users. We created a proxy indicator for disease severity. The first stage was defined as current use of either a biguanide or a sulfonylureum, the second stage as current use of a biguanide and a sulfonylureum at the same time, the third stage was assigned to patients using TZDs and the fourth stage to patients using insulin. Results: The risk of osteoporotic fracture was increased 1.5‐fold (HR 1.49, 95%CI 1.28–1.73) in patients who currently used TZDs (stage 3), and for patients using insulin (stage 4), the risk was increased 1.2‐fold (HR 1.24, 1.14–1.36), as compared with controls. In the first and second stages, risks were lower: HR 1.11 (1.06–1.17) for stage 1 and HR 1.03 (0.96–1.11) for stage 2. Conclusions: When observational studies assess risk of fracture in patients with TZDs, the severity of T2DM should be taken into account. Copyright © 2012 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FRAX™ and the assessment of fracture probability in men and women from the UK
Kanis, J. A., Johnell, O., Oden, A., Johansson, H., & McCloskey, E. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0543-5 · Cited by 2,467
Use of oral corticosteroids and risk of fractures
Van Staa, T. P., Leufkens, H. G. M., Abenhaim, L., Zhang, B., & Cooper, C. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.993 · Cited by 1,263
Self-citationNguyen, N. T., Nguyen, X.-M. T., Lane, J., & Wang, P. (2011) · Obesity Surgery · doi:10.1007/s11695-010-0335-4 · Cited by 385
Cited by
Fracture risk in diabetic elderly men: the MrOS study
Napoli, N., Strotmeyer, E. S., Ensrud, K. E., Sellmeyer, D. E., Bauer, D. C., Hoffman, A. R., Dam, T.-T. L., Barrett-Connor, E., Palermo, L., Orwoll, E. S., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3289-6 · Cited by 272
Driessen, J. H. M., Henry, R. M. A., van Onzenoort, H. A. W., Lalmohamed, A., Burden, A. M., Prieto-Alhambra, D., Neef, C., Leufkens, H. G. M., & de Vries, F. (2015) · Calcified Tissue International · doi:10.1007/s00223-015-9993-5 · Cited by 79
“For instance, thiazolidinediones [4–6] have shown to increase fracture risk.”
Self-citationShen, W.-R., Kimura, K., Ishida, M., Sugisawa, H., Kishikawa, A., Shima, K., Ogawa, S., Qi, J., & Kitaura, H. (2018) · Journal of Immunology Research · doi:10.1155/2018/5783639 · Cited by 45
DPP-4 inhibitor impedes lipopolysaccharide-induced osteoclast formation and bone resorption in vivo
Ishida, M., Shen, W.-R., Kimura, K., Kishikawa, A., Shima, K., Ogawa, S., Qi, J., Ohori, F., Noguchi, T., Marahleh, A., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.052 · Cited by 36
Metadata
- Authors
- Bazelier, M. T., Gallagher, A. M., van Staa, T., Cooper, C., Leufkens, H. G. M., Vestergaard, P., & de Vries, F.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2012-03-06
- Volume
- 21
- Issue
- 5
- Pages
- 507-514
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W2119840666
- Cited by
- 29
- References
- 3
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.